TY - JOUR
AU - Moreno-Torres, Irene
AU - Lallana, Virginia Meca
AU - Costa-Frossard, Lucienne
AU - Oreja-Guevara, Celia
AU - Aguirre, Clara
AU - Suárez, Elda María Alba
AU - Moreno, Mayra Gómez
AU - Canelo, Laura Borrega
AU - Muñoz, Julia Sabín
AU - Aladro, Yolanda
AU - Cárcamo, Alba
AU - García, Elena Rodríguez
AU - Cuello, Juan Pablo
AU - Monreal, Enric
AU - Sainz de la Maza, Susana
AU - Pérez Parra, Fernando Pérez Parra
AU - Valenzuela Rojas, Francisco
AU - López de Silanes de Miguel, Carlos
AU - Casanova, Ignacio
AU - Martínez Gines, Maria Luisa
AU - Blasco, Rosario
AU - García, Aida Orviz
AU - Villar-Guimerans, Luisa María
AU - Fernández-Dono, Guillermo
AU - Elvira, Victor
AU - Santiuste, Carmen
AU - Espiño, Mercedes
AU - García Domínguez, José Manuel
PY - 2021
DA - November
TI - Risk and outcomes of COVID-19 in patients with multiple sclerosis
JO - European Journal of Neurology
EP - 3721
VL - 28
IS - 11
DO - https://doi.org/10.1111/ene.14990
AB - Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.
PB - Wiley
UR - https://www.research.ed.ac.uk/en/publications/5c78a1b6-11af-46d2-b885-58869838c58a
KW - Coronavirus (COVID-19)
ER